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Abstract 
Orexins play a role in sleep regulation and orexin receptor antagonists are under 
development for the treatment of insomnia. We conducted a randomised, double-blind, 
placebo-controlled, four-period crossover study to investigate the effect of single doses of the 
dual orexin receptor antagonist SB-649868 (10 or 30 mg) and a positive control zolpidem (10 
mg), an allosteric modulator of GABAA receptors. Objective and subjective sleep parameters 
and next day performance were assessed in 51 healthy male volunteers in a traffic noise 
model of situational insomnia. Compared to placebo, SB-649868 10 and 30 mg increased 
Total Sleep Time (TST) by 17 and 31 minutes (p<0.001), whereas after zolpidem TST was 
increased by 11.0 min (p=0.012). Wake after sleep onset was reduced significantly by 14.7 
min for the SB-6489698 30 mg dose (p<0.001). Latency to persistent sleep was significantly 
reduced after both doses of SB-6489698 (p=0.003) but not after zolpidem. Slow Wave Sleep 
(SWS) and EEG power spectra in nonREM sleep were not affected by either dose of SB-
640868, whereas SWS (p< 0.001) and low delta activity (<=1.0Hz) were increased, and 2.25-
11.0Hz activity decreased after zolpidem. REM sleep duration was increased after SB-
649868 30 mg (p=0.002) and reduced after zolpidem (p=0.049). Latency to REM sleep was 
reduced by -20.1 (p=0.034) and -34.0 min (p<0.001) after 10 and 30 mg of SB-649868. Sleep 
onset REM episodes were observed. SB-649868 was well tolerated. This dual orexin receptor 
antagonist exerts hypnotic activity, with effects on sleep structure and the EEG that are 
different from those of zolpidem.   
 
Keywords: insomnia, orexin, hypocretin, hypnotics, circadian, GABA, SB-649868.   
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Introduction 
Insomnia is a serious health problem with an estimated prevalence ranging from 
approximately 4-22 % (Roth et al. 2011) and  associated costs which are significant (Sarsour 
et al. 2011). Current pharmacological treatments of insomnia are based primarily on positive 
allosteric modulators of several GABAA receptor subtypes, i.e., benzodiazepines and non-
benzodiazepines such as zolpidem (Nutt and Stahl 2010; Winsky-Sommerer 2009). Several 
novel pharmacological treatments for insomnia are under development including antagonists 
of the orexin 1 and orexin 2 receptors (OX1R, OX2R) (Scammell and Winrow 2011; Sullivan 
and Guilleminault 2009). The development of OXR antagonists for the treatment of insomnia 
is based on the large body of evidence supporting a role for orexin neuropeptides (also known 
as hypocretins) in the control of arousal and sleep/wake states (Brown et al. 2001; Eriksson et 
al. 2001; Eriksson et al. 2004; Eriksson et al. 2010; Hagan et al. 1999; Piper et al. 2000; 
Sakurai and Mieda 2011). In particular, (1) Orexin-producing neurons in the lateral 
hypothalamus exhibit high firing rates during wakefulness which dissipate during nonREM 
and REM sleep (Lee et al. 2005) and orexins activate the key neurotransmitter systems 
implicated in maintaining wakefulness, such as histamine, serotonin and noradrenaline, as 
well as cholinergic neurons (Sakurai and Mieda 2011); (2) Deficiency in the orexinergic 
system is associated with disruption of the sleep-wake cycle. This is observed in human 
narcolepsy-cataplexy, in canine and rodent animal models of human narcolepsy (i.e., knock-
out (KO), in mice devoid of either the prepro-orexin precursor or the orexin receptors and in 
transgenic mice and rats with selective postnatal degeneration of orexin-expressing neurons) 
(Chemelli et al. 1999; Mignot 2004; niz Behn et al. 2010; Sakurai and Mieda 2011); (3) 
Orexin concentrations in CSF fluctuate with a circadian rhythm which is synchronized to the 
wake-sleep cycle with peaks during the day in the day-active squirrel monkey (Zeitzer et al. 
2003) and during the night in the nocturnal rat (Deboer et al. 2004); (4) The circadian 
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variation in orexins is abolished by lesioning of the suprachiasmatic nuclei, the locus of the 
circadian pacemaker in mammals, which drives the circadian variation in sleep propensity 
and structure (Deboer et al. 2004).    
To our knowledge, until recently the only data available on effects of dual orexin 
receptor antagonists on sleep in humans are those recently published by Brisbare-Roch and 
colleagues (Brisbare-Roch et al. 2007). The authors reported on the effect of almorexant on 
sleep propensity and the electroencephalogram (EEG) in sleep recorded during two 25 min 
sessions during the daytime in healthy volunteers. Thus, there are currently only very limited 
data available on the effects of dual orexin receptor antagonists on sleep propensity and 
structure, as well as on the sleep EEG in humans. Furthermore, it is unknown how such 
effects compare to the effects of allosteric modulators of GABAA receptors, which are 
currently the most commonly prescribed hypnotics for the treatment of insomnia.  
 SB-649868 is a potent, orally acting, selective OX1/OX2 receptor antagonist under 
investigation for the treatment of insomnia. Studies in rodent and primate models have 
demonstrated sleep-promoting effects and lack of motor impairment following administration 
of SB-649868 (Gerrard et al. 2009). In healthy volunteers, SB-649868 was shown to be safe 
and well-tolerated at doses up to 80 mg, with mechanism-related adverse events (e.g., 
somnolence and fatigue) observed in a majority of subjects after 60 and 80 mg single doses. 
Evening administration of doses up to 60 mg to healthy volunteers without sleep complaint 
and under normal sleeping conditions resulted in significant dose-dependent decrease in 
latency to persistent sleep, and wake after sleep onset, and increase in total sleep time as 
measured by polysomnography (Bettica et al. 2011). 
We here assess and compare the effect of SB-649868 on sleep structure and the 
spectral composition of the sleep EEG and those of zolpidem, a non-benzodiazepine 
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allosteric modulator of GABAA receptor subtypes, relative to placebo, in a validated model of 
situational insomnia.  
 
Materials and Methods 
This was a randomised, double-blind, double dummy, placebo-controlled, four-period 
crossover study (Study code: GSK104094; ID# NCT00440323 on http://ClinicalTrials.gov) 
to investigate the effect of single oral doses of SB-649868 (10 or 30 mg) and of a positive 
control (zolpidem, 10 mg) in a model of noise induced situational insomnia in healthy male 
volunteers (Cluydts et al. 1995). In this model disruption of sleep maintenance and initiation 
is induced by standardized traffic noise and efficacy of hypnotics can be assessed reliably 
(Cluydts et al. 1995; Dijk et al. 2007; Dijk et al. 2011);  
The study was conducted at a single site (Surrey Clinical Research Centre, University 
of Surrey) and the protocol was approved by Ravencourt Ethics Committee, which is a Phase 
1 Research Ethics committee. The primary objective of the study was to determine the effect 
of SB-649868 on total sleep time, a measure of hypnotic efficacy comprising both sleep 
initiation and sleep maintenance elements, in healthy volunteers undergoing a noise-disturbed 
sleep model. Secondary objectives were to study: a) the changes induced by SB-649868 and 
zolpidem on other polysomnography (PSG) sleep parameters such as the nonREM sleep 
stages 1,2, 3, 4, REM sleep, the number of awakenings as well as the spectral composition of 
the sleep EEG; b) to investigate the effects of SB-649868 and zolpidem on subjective sleep 
quality, on the morning after dosing and on the following 3 days; c) to investigate the effects 
of SB-649868 and zolpidem on daytime cognitive functioning on the morning following 
dosing, and d) to investigate the safety and the pharmacokinetic profile of SB-649868 and 
zolpidem in healthy volunteers. Under the conditions and dose range used in the present 
study SB-649868 has been reported to have a half-life in the range of 3.4 h to 3.9 h (Bettica et 
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al. 2011). In this report we will focus on the primary outcome measures, as a prime indicator 
of hypnotic efficacy, as well as on the sleep related secondary outcome variables. 
Population: All subjects provided written informed consent to participate in the study 
and were screened approximately 28 days prior to treatment. Fifty-one subjects entered the 
study; 44 subjects completed the study while 7 subjects prematurely discontinued. Subjects 
were healthy adult males aged 18 – 55 years inclusive with a body weight ≥50 kg and a body 
mass index within the range 18.5 – 29.9 kg/m2. Subjects were to have a history of going to 
bed from 22:00 to 00:00 on at least 5 –7 nights per week with a reported nightly sleep 
duration of 6.5 – 8.5 h over the previous 3 months or more at Screening. Subjects who had 
consumed beverages and medications that could interfere with the effects of treatments or 
study assessments were excluded. Other key exclusion criteria were sleep apnoea and 
periodic limb movements’ disorders and other sleep disturbances, as assessed during a 
clinical polysomnographic screening, sleep complaints, and a recent history of or current shift 
work. Subjects who were not prepared to use protocol-specified methods of contraception or 
sexual abstinence, as appropriate, could also not be included. All subjects had to have 
laboratory values, vital signs and electrocardiographic (ECG) values within the normal 
reference range.  
Study Design and Treatments: The study consisted of four treatment sessions. Each 
treatment session consisted of 2 nights (Fig.1). Subjects were admitted to the unit on Day 1 at 
approximately 16:00 in the afternoon, prior to the first night (Night 1), and underwent 
admission procedures. At approximately 18:00, subjects were served a standard light snack, 
and at approximately 21:00 a standardised dinner was served. At approximately 22:30 they 
retired to bed with lights off at 23:00 and lights on at 07:00. During Night 1, study 
medication was not administered and subjects underwent PSG monitoring only (no noise 
disturbance).  
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During the second night (Night 2) for all sessions, after a standard light snack at 
approximately 18:00 and a standardised dinner at approximately 21:00, randomised subjects 
were administered two double-blinded doses of study medication.  Thirty minutes after a 
standard dinner, at approximately 21:30, subjects received either placebo or SB-649868 (10 
mg or 30 mg). This timing of administration was chosen because within the used dose range 
and administered in the fed state average tmax is approximately in the 2.5-2.75 h range 
(Bettica et al. 2011). At approximately 22:30 subjects received either placebo or zolpidem 
(10 mg). Subjects retired to bed at 22:30 with lights off at 23:00 (Fig. 1). 
During Night 2, subjects underwent PSG monitoring, blood sampling for 
pharmacokinetic analysis (before lights off) and were exposed to the pre-recorded traffic 
noise. Calibrated noise lasted from lights off (23:00) continuously until lights on (07:00). 
All subjects remained in the unit during each of the treatment sessions. Subjects were 
discharged at the end of each treatment session when all study procedures had been 
completed at the discretion of the Investigator depending on the nature of any ongoing 
adverse events. During the study, each single-dose treatment was separated by a 7-day 
washout period (±1 day) and preferably occurred on the same day of the week, or were 
consistently held on either workdays or days of rest, for any given subject. Subjects were 
instructed to maintain a normal pattern of sleep between 23:00 and 07:00 when outside the 
unit between treatment sessions. Compliance with the maintenance of a regular sleep-wake 
cycle instruction was monitored by actigraphy recordings for the duration of the study. 
Subjects were instructed to return to the unit within 7 – 14 days of the last dose of study 
treatment for the follow up visit. 
EEG/PSG recordings: Nine EEG channels (C4-A1, C3-A2, O2-A1; O1-A2, Fpz-
A1,Fz-A1,Cz-A1, Oz-A1, Pz-A1), two electrooculogram (EOG) channels and one submental 
electromyogram (EMG) channel, using gold electrodes were recorded onto a Compumedics 
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Siesta digital EEG machine. Signals were digitized at 256 (EEG, EMG) or 128 Hz 
(EOG/ECG) and stored at 128 Hz for the EEG and EOG/EMG. The low and high frequency 
filters were set at 0.3 and 70 Hz for the EEG/EOG and at 10 and 70 Hz for the EMG. A 
single channel ECG was also recorded. For the PSG screening night, this montage was 
complemented by recordings from the left and right Anterior Tibialis muscle, recording of 
nasal/oral airflow, thoracic and abdominal effort, body position, tracheal microphone and 
oximetry. All PSG were scored according to the standard criteria of Rechtschaffen and Kales 
(Rechtschaffen and Kales 1968). Epochs annotated as artefacts were excluded from the 
analyses of the EEG power spectra by visual inspection of the records while blind to 
treatment. Nights were only included in the spectral analysis if at least 5 hours of artefact free 
data were available. EEG spectral analysis was performed on the C3-A2 and C4-A1 channel 
using a fast Fourier transform, as previously described (Dijk et al. 2010). Briefly, EEG power 
spectra were computed per 4 s epochs and the 0.25 Hz spectra were collapsed into 1Hz bins. 
Average spectra were computed separately for nonREM sleep (encompassing stages 1-4) and 
REM sleep for C3-A2 or, if this channel was not available, C4-A1.  
Assessments: Treatment effects on sleep duration, maintenance and initiation were 
assessed by quantifying Total Sleep Time (TST), Wake After Sleep Onset (WASO), Number 
of Awakenings (NAW), Sleep Efficiency (SE), Latency to Persistent Sleep (LPS) and 
Latency to REM sleep as measured with PSG. In addition we assessed effects on sleep 
structure, i.e., REM sleep and nonREM sleep and its sub-stages 1,2,3,4 as well as Slow Wave 
Sleep (SWS) which is the sum of stage 3 and 4. Sleep questionnaires were used to assess 
subjective TST, subjective WASO, subjective NAW, subjective sleep latency, and sleep 
quality. A computerised battery of standard tests was used to assess treatment effects on 
subjective alertness, mood, working/short-term memory, long-term memory, 
attention/executive functions, and motor control. The battery, comprising three blocks of 
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tests, was used on the morning after dosing, beginning approximately 30 minutes after 
waking (i.e.,10 h post-dose for SB-649868 and 9 h post-dose for zolpidem), and ending 
approximately 90 minutes later. While the battery enables assessment of a wide range of 
functions, here we report the effects on two widely used tests of residual effects: 
Psychomotor Vigilance Task (PVT), which lasted for 10 minutes and Digit-Symbol 
Substitution (DSST), which was administered in each of the three test blocks. 
Treatments safety was assessed by collecting adverse events, vital signs, 12-lead ECG 
and clinical laboratory assessments. Plasma concentrations were assessed at different time-
points after the administration of both SB-649868 and zolpidem. 
Statistical analysis: A sample size of 46 subjects completing the study was planned as 
it would have provided 80% power to detect a difference between SB-649868 and placebo of 
at least 22 minutes in total sleep time, assuming a within-subject standard deviation of about 
36.8 minutes. A pre-specified interim analysis was performed when approximately half of the 
subjects had completed the study and showed that no sample size adjustment was required, 
because the variability of the data collected was in line with that expected.  
Available data from withdrawals were used for all statistical analyses, as planned in 
the protocol and as properly managed by the mixed models applied. For the final analysis, a 
mixed-effects model was applied on PSG data of the 2nd nights, with period and treatment as 
fixed effects and subject as random effect. Estimates for mean treatment differences of SB-
649868 compared with placebo and with zolpidem were derived. Similar estimates were 
provided for zolpidem compared with placebo. Tests of significance were performed at the 
5% level.  
Subjective Sleep Questionnaire data were also analysed in this mixed model with the 
pre-dose’ values included as a ‘baseline’ covariate.  
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Measures of DSST and PVT underwent an exploratory analysis of covariance 
(ANCOVA). Cognitive performance after the night with No-Noise Exposure (baseline) was 
used as a covariate, period and treatment as fixed effects and subject as random effect. 
Estimates for mean treatment differences of SB-649868 compared with placebo were derived. 
In an exploratory analysis of the effects of treatment on EEG power spectra, nonREM 
and REM sleep spectra in each of the three treatments were expressed as a percentage of the 
placebo condition for each individual and geometric means and 95% confidence intervals 
were computed for each of the conditions. 
Safety data were summarised by means of descriptive statistics. 
 
Results 
Subject disposition 
Fifty-one healthy men were recruited, and received at least one treatment. Forty four 
subjects completed the study as planned. Baseline characteristics of the subjects are reported 
in Table 1.  
Effects on sleep maintenance and initiation 
A summary of the effects of placebo, of SB-649868 (10 and 30 mg) and of zolpidem 
(10 mg) is presented in Table 2. 
Although a baseline no-noise condition was not recorded in this study, sleep in the 
placebo condition showed the disruptive effects of the model on sleep, i.e., a long LPS and 
relatively low sleep efficiency (87%), reflecting a TST of only 419 min. When compared to 
placebo both doses of SB-649868 significantly increased TST by 17 and 31 min for the 10 
mg and 30 mg dose respectively. A significant increase in TST was also observed after 
zolpidem, although to a lower extent (+11 min). The increase in TST after SB-649868 10 mg 
was not significantly different from zolpidem, but the increase after SB-649868 30 mg was 
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statistically significantly greater than after zolpidem. The significant changes in TST were 
accompanied by significant changes in SE (%). WASO was significantly reduced for the 
SB-648969 30 mg dose, but not so for the other active treatments, although the improvement 
of around 7 min obtained with the 10 mg dose was already of the same extent of that 
estimated for zolpidem. The number of awakenings was not significantly different from 
placebo for any of the treatments. LPS was significantly reduced after both doses of 
SB-648969 (of -8.5 and -17.4 min at 10 mg and 30 mg respectively) while the effect of 
zolpidem on LPS was not statistically significant.   
Effects on Sleep Structure and the EEG 
All-Night Measures: SB-649868 and zolpidem had different effects on sleep 
architecture. When analysed as % of sleep period time, SB-649868 did not affect nonREM 
sleep with the exception of a significant prolongation of Stage 1 observed for SB-649868 10 
mg. By contrast, zolpidem significantly increased the % of sleep period time spent in Stage 3 
and 4 and SWS. Furthermore, with regard to REM sleep SB-640868 30 mg significantly 
increased the % of sleep period time spent in REM sleep, while a significant reduction in % 
sleep period time spent in REM sleep was observed with zolpidem 10 mg. Latency to REM 
sleep was reduced after both doses of SB-649868. Analysis of the distribution of REM 
latencies is presented in Figure 2. Sleep onset REM latencies, i.e., intervals between sleep 
onset and the first occurrence of REM sleep less than or equal to 15 minutes were observed 
for SB-640868 10 mg (n=1) and 30 mg (n=2), but not for placebo (n=0) or zolpidem (n=0). 
Analyses per Third of Sleep Episode. The effects of the treatment on REM sleep and 
SWS were also analyzed per third of the sleep episode. REM sleep increased from the first to 
the final third whereas SWS decreased in all conditions (Fig. 3). In the first third REM sleep 
was increased compared to placebo for both SB-649868 10 and 30 mg. In the second third a 
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significant increase compared to placebo was only observed after SB-649868 30 mg and no 
significant differences from placebo were observed for REM sleep in the final third.  
In the first third of the sleep episode, SWS was enhanced compared to placebo after 
both SB-649868 30 mg and zolpidem. In the second third a significant increase of SWS was 
only observed after zolpidem and in the final third no statistically significant differences from 
placebo were present. 
SB-649868 did not alter the EEG power density in either nonREM sleep (Fig. 4) or 
REM sleep (data not shown), i.e., all values were close to placebo. In contrast, during 
nonREM sleep zolpidem increased EEG power density in the 0.25-1.0 Hz bin while a 
decrease was observed for frequencies between 2.25 and 11Hz (Fig. 4). 
Subjective sleep measures 
Subjective sleep measure assessed in the morning following baseline sleep (i.e., no 
noise) and the morning following noise exposure are presented separately for placebo, SB-
649868 (10 and 30 mg) and of zolpidem (10 mg) in Table 3. Exposure to the noise model was 
associated with an increase in subjective sleep latency, and the number and duration of night 
awakenings and a reduction in subjective total sleep time in particular in the placebo 
condition. The effects of the treatments on subjective sleep assessments were quite variable 
although all treatments appeared to counter the negative effects of the noise model to some 
extent. Significant improvements compared to placebo were only observed for subjective 
sleep latency (p=0.029) and subjective total sleep time (p=0.008) after treatment with the SB-
649868 30 mg dose. 
Performance 
Performance across all tests was consistently high, indicating that participants were 
well motivated.  
Digit Symbol Substitution Test.   
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Performance on the DSST is summarized by presenting the number of correct 
responses during the three assessments at baseline and following noise exposure, separately 
for the three treatments (Table 4). Mean and median numbers of correct responses were 
consistently high. Median correct responses varied from 14-15 whereas the median number 
of attempted response varied from 15-16. ANCOVA did not detect any significant 
differences from placebo. 
Psychomotor Vigilance Task 
Performance on the PVT was summarized by presenting the number of lapses 
(response time > 500 ms) and the median response times (Table 5). For lapses some 
indication of an effect of treatment was present in the SB-649868 30 mg condition in which 
according to the ANCOVA the mean number of lapses was significantly greater than in the 
placebo condition (p=0.012). The median number of lapses was 1 in all conditions. The 
average median response time was short in all conditions, with some indication of an increase 
in the average median response time in the SB-649868 30 mg condition (p=0.013 vs. 
placebo). However, also in the SB-649868 30 mg condition the median of the median 
response time was identical to placebo. 
Adverse Events 
Overall, the frequency of adverse events was similar for the active treatment groups 
and placebo. Table 6 reports the most frequent adverse events, i.e., those reported by at least 
5% of the subjects. More than twice as many subjects reported somnolence and disturbance 
of attention after SB-649868 30 mg compared to placebo. On the other hand, headache was 
reported in more than twice as many subjects after placebo compared to the other treatments 
and insomnia was reported in more than twice as many subjects after placebo compared to 
SB-649868 30 mg. Most of the adverse events were mild or moderate in intensity. Only one 
subject experienced an adverse event of severe intensity (severe somnolence after receiving 
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SB-649868 30 mg that was judged by the Investigator to be related to investigational 
product). One subject reported a mild hallucination which started 90 minutes after the 
administration of SB-649868 30 mg and lasted 2 hours; the adverse event recovered and the 
subject continued the study. There were no clinically relevant abnormalities in urinalysis, 12-
lead ECG and vital signs parameters.  
 
Discussion 
This is a first report of the effects of the orexin receptor 1 and 2 antagonist SB-649868 
on sleep and the EEG in a traffic noise model of situational insomnia. Sleep under placebo 
conditions showed the characteristic disruptive effect of this validated model (Cluydts et al. 
1995) on PSG assessed sleep initiation and total sleep time as well as subjective measures of 
sleep initiation. These disruptive effects were countered to some extent by the active 
treatments. Both doses (10 and 30 mg) of SB-649868 showed significant hypnotic efficacy as 
indexed by a significant increase in total sleep time and a reduction in the latency to 
persistent sleep. The effects on total sleep time are not only due to the reduction in the latency 
to sleep onset because wakefulness after sleep onset was reduced after SB-649868 30 mg. 
Thus these data indicate that SB-649868 has positive effects on both sleep initiation as well 
as sleep maintenance, as indexed by wake after sleep onset. Number of awakenings, on the 
other hand, was not affected by SB-649868. The effects observed in this study are in line with 
those observed in healthy volunteers in normal sleeping conditions (Bettica et al. 2011). Also 
in that case SB-649868 did not affect the number of awakenings. As we cannot say whether 
noise disturbance significantly disrupted number of awakenings, we cannot conclude an SB-
649868 effect on number of awakenings. The positive control (zolpidem 10 mg) showed its 
well established hypnotic efficacy as indexed by an increase in total sleep time. Interestingly, 
the effect on total sleep time was greater for SB-649868 30 mg than zolpidem. Zolpidem did 
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not improve sleep initiation in this study, but, compared to SB-649868 30 mg, led to a greater 
reduction in the number of awakenings. The effects of dual orexin receptor antagonists on 
sleep initiation and total sleep time are likely to be mediated by a reduced orexinergic drive 
on several neuronal populations known to play a key role in the transitions between 
wakefulness and sleep and to be densely innervated by the orexin-producing neurons. These 
include the monoaminergic noradrenergic neurons of the locus coeruleus and serotonergic 
neurons of the raphe nuclei, expressing respectively OX1R and OX1R/OX2R, as well as the 
histaminergic neurons located in the tuberomammillary nucleus via OX2R (Fort et al. 2009; 
Mieda et al. 2011). Thus, dual orexin receptor antagonists may exert their effects by reducing 
the excitatory action of orexins on these wake-promoting neurostransmitter systems, resulting 
in a decreased monoaminergic tone, which in turn will reduce cortical activation and an 
increased sleep propensity. In addition,  dual orexin receptor antagonists may exert their 
effects on cholinergic neurons of the basal forebrain and of the latero-dorsal tegmental (LDT) 
and pedunculopontine tegmental (PPT) nuclei that are part of the arousal-promoting circuits 
(Fort et al. 2009). Zolpidem acts through a positive allosteric modulation of GABAA 
receptors, showing a preferential affinity for the α1-GABAA receptor subtype and lower 
affinity to α2- and α3-GABAA receptor subtypes (Mohler 2006; Winsky-Sommerer 2009). 
Whether and how these differential effects on total sleep time and number of awakening 
relate to the different roles of these specific GABAA subtypes and the orexinergic system in 
‘sleep state switching’ (Fort et al. 2009; Saper et al. 2010) cannot be determined from our 
data.  
The effects on sleep structure differed between the two compounds such that the 
percentage of sleep period spent in the SWS stage was enhanced after zolpidem and not 
affected by SB-649868, whereas the percentage of sleep period spent in REM sleep was 
enhanced after SB-649868 and reduced after zolpidem. SB-649868 enhanced REM sleep 
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propensity as evidenced by both an increase in REM sleep duration and a reduction in REM 
latency. Enhancement of visually scored SWS by zolpidem has been reported previously 
(Kanno et al. 2000). In this study, zolpidem led to an increase in EEG activity in the 0.25-1.0 
Hz range and a reduction in higher delta and theta frequencies, consistent with previous 
reports (Brunner et al. 1991; Dijk et al. 2010). The lack of an effect of SB-649868 on EEG 
power spectra in nonREM sleep in the present study can therefore not be attributed to a lack 
of sensitivity of spectral measures in this model of situational insomnia. Suppression of REM 
sleep by benzodiazepines is also well documented although for zolpidem and other non-
benzodiazepine allosteric modulators of the GABAA receptor this effect is not always 
observed (Lancel 1999;Mohler 2006). Effects of dual orexin receptor antagonists on REM 
sleep have been previously shown in animals (e.g., Brisbare-Roch et al. 2007; Gerrard et al. 
2009) and humans possibly mediated at least in part by their effects on LDT/PPT cholinergic 
neurons implicated in REM sleep regulation (Sakurai and Mieda 2011). This would be in 
accordance with previous studies in cats showing that microinjection of orexin-A in the LDT 
significantly suppressed REM sleep (Xi et al. 2001). In addition, REM-off noradrenergic and 
serotonergic neurons, located respectively in the locus coeruleus and the raphe nuclei, are 
known to be implicated in the control of the gating to REM sleep (Luppi et al. 2011), and to 
display high expression levels of OX1R and OX1R/OX2R respectively (Mieda et al. 2011). 
Thus, SB-649868 is likely to suppress serotonergic and noradrenergic transmission that 
would counteract REM sleep suppression by, in part, reducing the noradrenergic excitation of 
REM-off neurons in the dorsal deep mesencephalic reticular nucleus (Crochet et al. 2006). 
Furthermore, a recent study suggested that suppression of REM sleep by orexin-A involves 
both O1X and OX2 receptors (Mieda et al. 2011). Thus the effects of the dual orexin receptor 
antagonist on sleep structure as assessed by visual scoring of polysomnographic records, is 
very different from the effects of zolpidem even though both compounds have hypnotic 
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effects. Quantitative EEG analysis of the nonREM EEG further differentiated the effects of 
these compounds. While zolpidem altered the nonREM sleep EEG in accordance with the 
extensively described benzodiazepine EEG fingerprint shared by non-benzodiazepine 
compounds, SB-649868 did not induce noticeable changes in the EEG power density. 
Overall, our results suggest that the dual orexin antagonist receptor SB-649868 exerts 
direct or indirect effects on several transmitter systems involved in the transitions between 
vigilance states, while it does not -at least at the 10 and 30 mg doses- alter neuronal networks 
involved in the generation of EEG rhythms. 
The characteristic dynamics of sleep structure across the sleep episode when sleep 
occurs during the night, i.e., a decline of SWS and an increase in REM sleep (Dijk and 
Czeisler 1995) was preserved in all conditions indicating that major regulatory process 
underlying sleep are not significantly disrupted by either the traffic noise model or the 
pharmacological treatments. 
The distribution of REM sleep latencies as observed after SB-649868 is reminiscent 
of the bimodal distribution which has been observed in disorders such as depression and has 
been successfully simulated based on mathematical models of REM sleep regulation 
(Beersma et al. 1984). 
Some neuronal pathways involved in the control of autonomic function, as well as 
several regions of the limbic system, associated with stress, emotions and anxiety, provide 
neuronatomical and physiological input onto orexinergic neurons (Yoshida et al. 2006) and 
may contribute to hyper-arousal associated with insomnia and orexin antagonists may reduce 
this arousal. We note that a limitation of the traffic noise insomnia model is that some of the 
arousal circuits activated may be different from those activated in insomnia. 
The Digit Symbol Substitution Task is a sensitive task to assess residual effects (e.g., 
Boyle et al. 2009; Stone et al. 2002). In the present study neither of the two doses of SB-
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649868, nor 10 mg of zolpidem induced residual effects on the DSST. The absence of an 
effect of zolpidem is in accordance with previous studies (Hindmarch et al. 2001). 
Performance on the psychomotor vigilance task (PVT), a task used extensively to document 
the negative effects of sleep loss (e.g., Lim and Dinges 2008) did also not indicate major 
residual effects, although for the SB-649868 30 mg dose some indication for reduced 
performance on this task was observed.  
 
Both SB-649868 and zolpidem were well tolerated. Adverse events which were most 
frequent and which occurred, more often after SB-649868, were related to its 
pharmacological effect. This result is in line with what previously reported in healthy 
volunteers who received SB-649868 in the morning, after lunch or after dinner (Bettica et al. 
2011). Somnolence was reported by 29% of subjects treated with SB-649868 30 mg. This is 
not unexpected considering the potent sleep-inducing effect of SB-649868, the fact that 
dosing was timed to maximize the hypnotic effect, i.e., subjects were dosed 90 minutes 
before bedtime, and that circulating levels of SB-649868 were still relatively high at lights on 
(data not shown). Future studies should explore different doses and dosing regimens of the 
drug both in healthy subjects and in the target patient population. 
 
Narcolepsy/cataplexy could be a possible consequence of orexin antagonism based on 
preclinical and human data suggesting a deficiency of the orexinergic system in narcolepsy 
(Chen et al. 2005). Symptoms common in narcolepsy/cataplexy are hallucinations, sleep 
paralysis, cataplexy and sleep onset REM episodes (SOREM) (Narcolepsy fact sheet, 
National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders). 
One mild hallucination was reported by a subject treated with SB-649868 30 mg and SOREM 
episodes were reported only after the administration of SB-649868. It should be noted that 
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also in this case the timing of drug administration two hours before lights out, may have 
artificially increased the risk of hallucinations and SOREM episodes. Future studies in 
patients and with different timing of dosing will be needed to assess the risk of SB-649868 to 
induce narcolepsy/cataplexy.   
 
Overall, these data indicate that the dual orexin receptor antagonist SB-649868 has 
significant hypnotic effects in a model of situational insomnia, with effects on REM sleep, 
SWS and the EEG that are different from those of zolpidem. These differences may be 
related to the different mechanisms of action of these two compounds.     
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Table 1. Baseline Characteristics of recruited subjects 
 
Demographic parameter  N = 51 
Age in Years, Mean (standard deviation) 28.9 (8.77) 
Sex, n (%)  Male: 51 (100) 
White, n (%) 39 (76) 
Body mass index in kg/m2, Mean (standard deviation) 24.08 (2.371) 
Height in cm, Mean (standard deviation) 177.0 (6.856) 
Weight in kg, Mean (standard deviation) 75.63 (10.177) 
 26 
Table 2. PSG Sleep Parameters 
 Mean (SD) Estimated difference 
vs Placebo (p-value) 
Estimated difference 
vsZolpidem (p-value) 
PSG 
Parameter 
Placebo 
 
 
n=45 
SB-649868 
10 mg 
 
n=45 
SB-649868 
30 mg 
 
n=45 
Zolpidem 
 
 
n=43 
SB-649868 
10 mg 
SB-649868 
30 mg 
 
Zolpidem 
SB-649868 
10 mg 
SB-649868 
30mg 
LPS (min) 27.2 
(23.1) 
18.8 
(19.2) 
9.0 
 (10.0) 
22.3 
 (10.9) 
-8.5 
(0.003) 
-17.4 
(<0.001) 
-3.8 
(0.180) 
-4.7 
(0.099) 
-13.6 
 (<0.001) 
NAW1 (#) 21.2 
(11.5) 
20.2 
(9.2) 
22.0 
(14.4) 
18.2 
(12.1) 
+0.1 
(0.956) 
+1.4 
(0.294) 
-2.5 
(0.069) 
+2.6 
 (0.064) 
+3.9 
 (0.005) 
REM (%) 18.3 
(4.0) 
19.2 
(4.6) 
20.8 
(4.5) 
17.1 
 (5.0) 
+0.8 
 (0.242) 
+2.3 
 (0.002) 
-1.4 
(0.049) 
+2.3 
 (0.002) 
+3.7 
 (<0.001) 
SE (%) 87.2 
 (7.9) 
90.7 
 (7.1) 
93.9 
 (4.4) 
89.9 
 (6.5) 
+3.5 
(<0.001) 
+6.4 
(<0.001) 
+2.3 
 (0.012) 
+1.2 
 (0.180) 
+4.1 
 (<0.001) 
ST1 (%) 10.4 
 (4.7) 
10.9 
 (6.0) 
10.7 
 (6.7) 
10.0 
 (6.2) 
+1.1 
 (0.039) 
+0.6 
 (0.290) 
+0.0 
 (0.969) 
+1.1 
 (0.046) 
+0.5 
 (0.316) 
ST2 (%) 50.7 
 (10.5) 
50.6 
 (8.8) 
51.1 
 (10.6) 
49.6 
 (8.6) 
-0.9 
 (0.396) 
0.1 
 (0.951) 
-1.4 
 (0.161) 
+0.6 
 (0.578) 
+1.5 
 (0.144) 
ST3 (%) 5.6 
 (2.4) 
5.9 
 (2.3) 
5.9 
 (2.4) 
6.4 
 (2.9) 
+0.2 
 (0.637) 
+0.2 
 (0.585) 
+0.7 
 (0.046) 
-0.6 
 (0.128) 
-0.5 
 (0.142) 
ST4 (%) 7.0 
 (6.6) 
7.1 
 (5.8) 
7.1 
 (5.4) 
11.5 
 (6.7) 
+0.3 
 (0.554) 
+0.2 
 (0.738) 
+4.5 
 (<0.001) 
-4.2 
(<0.001) 
-4.3 
 (<0.001) 
SWS (%) 12.5 
(7.7) 
12.9 
(6.8) 
13.0 
(6.5) 
17.9 
(7.1) 
+0.5 
 (0.428) 
+0.4 
 (0.539) 
+5.2 
(<0.001) 
-4.7 
(<0.001) 
-4.8 
 (<0.001) 
TST (min) 418.9 
 (38.0) 
435.9 
 (34.0) 
451.2 
 (21.2) 
431.9 
 (31.3) 
+16.8 
(<0.001) 
+30.7 
(<0.001) 
+11.0 
 (0.012) 
+5.8 
 (0.185) 
+19.7 
 (<0.001) 
WASO (min) 37.3 
 (27.0) 
30.2 
 (26.5) 
21.6 
 (19.8) 
29.5 
 (29.5) 
-6.5 
 (0.102) 
-14.7 
(<0.001) 
-6.8 
 (0.088) 
+0.4 
 (0.931) 
-7.9 
 (0.050) 
REM latency 
(min) 
142.9 
(57.3) 
121.6 
(54.6) 
106.9 
(48.6) 
139.6 
(58.5) 
-20.1 
(0.034) 
-34.0 
(<0.001) 
-0.6 
(0.949) 
-19.5 
(0.043) 
-33.4 
(<0.001) 
(#): NAW1= Number of awakenings after sleep onset 
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Table 3. Subjective Sleep Parameters 
[n]; Mean (SD) 
PSG Variable Night Placebo SB-649868 
10 mg 
SB-649868 
30 mg 
Zolpidem 
10 mg 
Baseline [38] 
17.3 
(12.3) 
[39] 
18.7 
(20.6) 
[39] 
18.2 
(12.6) 
[36] 
17.3 
(12.0) 
S-Sleep Latency 
(min) 
Noise 
Exposure 
[39] 
39.9 
(35.2) 
[40] 
50.0 
(84.3) 
[38] 
20.7 
(13.3) 
[34] 
38.4 
(36.6) 
Baseline [46] 
453.6 
(21.7) 
[47] 
446.1 
(48.4) 
[46] 
449.2 
(29.7) 
[45] 
452.9 
(22.4) 
S-Total Sleep 
Time (min) 
Noise 
Exposure 
[45] 
380.1 
(94.2) 
[48] 
395.5 
(97.6) 
[46] 
413.3 
(79.0) 
[45] 
394.5 
(93.0) 
Baseline [46] 
1.5 
(1.3) 
[47] 
1.7 
(2.1) 
[46] 
1.5 
(1.4) 
[45] 
1.4 
(1.3) 
S-Number of 
Awakenings 
Noise 
Exposure 
[46] 
3.6 
(4.4) 
[48] 
3.2 
(3.0) 
[47] 
3.4 
(3.2) 
[44] 
2.8 
(2.1) 
Baseline [42] 
11.5 
(13.6) 
[42] 
12.0 
(20.7) 
[41] 
14.6 
(19.4) 
[39] 
10.0 
(11.8) 
S-Wake After 
Sleep Onset (min) 
 
Noise 
Exposure 
[38] 
54.8 
(59.2) 
[42] 
37.6 
(41.5) 
[38] 
44.0 
(56.4) 
[35] 
35.3 
(42.4) 
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Table 4. Digit Symbol Substitution Test; Number Correct: [n]; Mean/Median (SD) 
Night/Measurement Placebo SB-649868 
10 mg 
SB-649868 
30 mg 
Zolpidem 
10 mg 
Baseline (1) [46] 
14.8/15 
(1.4) 
[48] 
14.3/14 
 (1.7) 
[48] 
14.5/14 
 (1.8) 
[45] 
14.5/14 
(1.7) 
Baseline (2) [46] 
14.3/14 
(1.5) 
[48] 
14.0/14 
(1.4) 
[48] 
14.1/14 
 (2.2) 
[45] 
14.3/14 
 (1.8) 
Baseline (3) [45] 
14.2/14 
(1.5) 
[48] 
14.2/14 
(1.6) 
[48] 
13.9/14 
 (1.9) 
[45] 
14.3/14 
 (1.6) 
Noise Exposure (1) [46] 
14.5/14.5 
(1.7) 
[48] 
14.5/14 
 (2.0) 
[48] 
14.3/14 
 (1.7) 
[45] 
14.8/15 
 (1.5) 
Noise Exposure (2) [46] 
14.5/14 
(1.5) 
[48] 
14.5/14 
 (1.6) 
[48] 
14.4/14 
 (1.5) 
[45] 
14.4/14 
 (1.8) 
Noise Exposure (3) [46] 
14.5/14 
(1.6) 
[48] 
14.7/15 
 (1.4) 
[47] 
14.3/15 
 (1.8) 
[45] 
14.4/15 
(1.9) 
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Table 5. Psychomotor Vigilance Task: [n]; Mean/Median (SD) 
Variable Night Placebo SB-649868 
10 mg 
SB-649868 
30 mg 
Zolpidem 
10 mg 
Baseline [45] 
2.0/1 
(3.1) 
[48] 
2.3/1 
(3.3) 
[48] 
2.8/1 
(3.8) 
[45] 
2.3/1 
(3.4) Lapses (number) 
 Noise 
Exposure 
[46] 
2.2/1 
(3.2) 
[48] 
1.9/1 
(2.9) 
[47] 
4.7/1 
(8.4) 
[45] 
2.1/1 
(2.9) 
Baseline 
 
[45] 
268/266 
(37) 
[48] 
267/264 
(30) 
[48] 
276/266 
(39) 
[45] 
270/262 
(40) Median Reaction 
Time (ms) Noise 
Exposure 
[46] 
268/263 
(37) 
[48] 
269/263 
(35) 
[47] 
286/263 
(59) 
[45] 
267/258 
39 
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Table 6. Summary of Adverse Events occurring in at least 5% of subjects 
 
Preferred Term 
 
Placebo 
(N=46) 
10 mg 
SB649868 
(N=48) 
30 mg 
SB649868 
(N=48)     
10 mg 
Zolpidem 
(N=45) 
Fatigue            9 (20%) 6 (13%) 10 (21%) 11 (24%) 
Vessel puncture site   
haematoma          
3  (7%) 2  (4%) 4  (8%) 4  (9%) 
Somnolence 2  (4%)           4  (8%)          14 (29%)    3  (7%) 
Headache 4  (9%)           1  (2%)           2  (4%)           1  (2%) 
Disturbance in 
attention 
1  (2%) 0 (0%) 3  (6%) 1  (2%) 
Insomnia 4  (9%) 6 (13%)           1  (2%)           3  (7%) 
Hypoglycaemia 3  (7%) 2  (4%) 5 (10%)      4  (9%) 
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Fig1. Schematic representation of the protocol. This was a four-period crossover study, each 
period consisting of two consecutive nights (Night 1: adaptation; Night 2: treatment). During 
Night 2 for all sessions, randomised subjects were administered two double-blinded doses of 
study medication (i.e., either placebo or SB-649868 (10 mg or 30 mg); or either placebo or 
zolpidem 10 mg), while exposed to the traffic noise model of situational insomnia 
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Fig2. Distribution of latency to REM sleep during the four 
conditions.
 33 
Fig 3. REM sleep and SWS per third of sleep episode during noise exposure after treatment 
with placebo, 10 mg SB-649868, 30 mg SB-649868 and 10 mg zolpidem. Error bars indicate 
1 SEM. * P<0.05; § P<0.01; # P<0.001, Compared to placebo 
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Fig 4. Effect of SB-649868 (10 and 30 mg) and zolpidem (10 mg) on EEG power density 
spectra during non REM sleep. All data are geometric means expressed relative to placebo 
(=100%). Vertical bars indicate 95% confidence intervals. 36-38 subjects contributed to each 
of the comparisons for frequencies up to 15 Hz. Data are plotted at the upper limits of the 
frequency bins. Thus, values plotted at 1 Hz represent the 0.25-1.0 Hz bin. 
 
